The U.S. Food and Drug Administration has cleared a new blood test for Alzheimer's disease, marking the fourth such approval in under two years and giving clinicians another tool to identify the disease earlier.
Roche announced Sunday that its Elecsys Phospho-Tau test, developed with Eli Lilly, received FDA approval. The test is designed for adults 55 and older who show signs, symptoms, or complaints of cognitive decline, and it can help physicians determine which patients should undergo further evaluation sooner.
Dan Malarek, president and CEO of Roche Diagnostics North America, called the clearance a milestone in Alzheimer's diagnosis. In a company statement, he said the test is the first and only FDA-cleared single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology, a hallmark of Alzheimer's. He added that it has the potential to transform how the disease is assessed across primary and specialty care.
The approval comes as the FDA has moved rapidly to embrace blood-based diagnostics for Alzheimer's. The first such test was cleared in May 2025, and since then regulators have approved three more, reflecting a broader shift toward less invasive and more accessible diagnostic methods.
Traditionally, Alzheimer's is diagnosed through cognitive testing, brain imaging, and by ruling out other conditions that could cause memory or thinking problems. These methods can be time-consuming and costly, and they often delay diagnosis until the disease has progressed significantly.
The Alzheimer's Association welcomed the approval in a statement Monday. The organization stressed that no single test can diagnose Alzheimer's on its own, but that new options like this one can be integrated with standard evaluation methods.
Maria C. Carrillo, the association's chief science officer, said each FDA clearance gives clinicians another validated option when evaluating patients with cognitive impairment. She called it real progress for a field that, for decades, had far too few tools to offer.
The approval also arrives amid broader political debates over healthcare access and innovation, as policymakers weigh how to balance regulatory speed with patient safety. The test's availability could ease pressures on the healthcare system by reducing the need for more invasive procedures like spinal taps, but questions remain about cost and insurance coverage.
Roche has not yet announced pricing or a launch timeline, but the company said it will work to make the test widely available. For now, the Elecsys pTau217 adds to a growing arsenal of blood tests that could reshape how Alzheimer's is detected and managed.
